Compare UNTY & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UNTY | ASMB |
|---|---|---|
| Founded | 1991 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 533.7M | 442.9M |
| IPO Year | 2014 | 2010 |
| Metric | UNTY | ASMB |
|---|---|---|
| Price | $53.79 | $31.17 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $65.00 | $44.20 |
| AVG Volume (30 Days) | 35.2K | ★ 123.6K |
| Earning Date | 04-14-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.23% | N/A |
| EPS Growth | 39.66 | ★ 91.78 |
| EPS | ★ 5.67 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.14 | N/A |
| Revenue Next Year | $9.56 | $638.39 |
| P/E Ratio | $9.36 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $41.67 | $11.95 |
| 52 Week High | $57.30 | $39.71 |
| Indicator | UNTY | ASMB |
|---|---|---|
| Relative Strength Index (RSI) | 54.51 | 63.50 |
| Support Level | $49.67 | $26.50 |
| Resistance Level | $57.03 | $32.44 |
| Average True Range (ATR) | 1.46 | 1.50 |
| MACD | -0.03 | 0.39 |
| Stochastic Oscillator | 66.65 | 88.18 |
Unity Bancorp Inc is a bank holding company that serves as a holding company for Unity Bank. The Company has elected to become a financial holding company pursuant to regulations of the Board of Governors of the Federal Reserve System (the FRB). The Company's primary business is ownership and supervision of the Bank. The Company and the Bank derive a majority of their revenue from net interest income (i.e., the difference between the interest received on loans and securities and the interest paid on deposits and borrowings). The Company, through the Bank, conducts a traditional and community-oriented commercial banking business and services, personal and business checking accounts, time deposits, money market accounts, savings accounts, credit cards, automated teller service, and others.
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.